Literature DB >> 7500834

Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1.

D K Lahiri1, C Nall.   

Abstract

Abnormalities in gene regulation of the beta-amyloid precursor protein (beta APP) might be an important factor in the neuropathology of Alzheimer's disease. We analyzed the effects of nerve growth factor (NGF), basic fibroblast growth factor (bFGF), phorbol 12-myristate 13-acetate (PMA), interleukin-1 (IL-1) and retinoic acid (RA) on promoter activity of the beta APP gene. To investigate the effect of these factors on promoter activity, we used two fusion plasmids which contain sequences of -489 and -415 base pairs (bp), respectively, from the transcription start site of the beta APP gene. The truncated regions of the promoter wer linked upstream to a reporter gene, chloramphenicol acetyl transferase (CAT). Promoter activity was tested by transient transfection of fusion plasmids in PC12 cells using the electroporation method (960 microF at 350 V). We report that the treatment of PC12 cells with either NGF, bFGF, PMA, IL-1 or RA stimulated the activity of the beta APP promoter. The treatment of cells with either NGF or bFGF resulted in a higher degree of stimulation in the basal level of promoter activity than when cells were treated with either PMA, IL-1 or RA. The deletion of sequences between -489 to -416 bp had no significant effect on promoter activity. The treatment of cells with these factors for a duration of 4 days prior to transfection with the plasmids is necessary for the stimulatory effect. The cells that were only treated with any of these factors after transfection showed no significant change in the basal level of promoter activity. We conclude that certain growth factors and a cytokine could enhance the basal level of promoter activity of the beta APP gene, suggesting a possible participation of a growth-factor(s)-mediated transcription element in the control of gene expression of beta APP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500834     DOI: 10.1016/0169-328x(95)00078-7

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  28 in total

1.  The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus.

Authors:  Y Gao; S W Pimplikar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

2.  MicroRNA-101 downregulates Alzheimer's amyloid-β precursor protein levels in human cell cultures and is differentially expressed.

Authors:  Justin M Long; Debomoy K Lahiri
Journal:  Biochem Biophys Res Commun       Date:  2010-12-21       Impact factor: 3.575

Review 3.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 4.  Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Authors:  Greg M Cole; Sally A Frautschy
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

5.  Rapid stimulation of amyloid precursor protein release by epidermal growth factor: role of protein kinase C.

Authors:  B E Slack; J Breu; L Muchnicki; R J Wurtman
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

6.  Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease.

Authors:  Jessie Theuns; Nathalie Brouwers; Sebastiaan Engelborghs; Kristel Sleegers; Veerle Bogaerts; Ellen Corsmit; Tim De Pooter; Cornelia M van Duijn; Peter P De Deyn; Christine Van Broeckhoven
Journal:  Am J Hum Genet       Date:  2006-04-10       Impact factor: 11.025

Review 7.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

Review 8.  Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders.

Authors:  Justin M Long; Debomoy K Lahiri
Journal:  Exp Neurol       Date:  2012-01-05       Impact factor: 5.330

9.  Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development.

Authors:  K T Shaw; T Utsuki; J Rogers; Q S Yu; K Sambamurti; A Brossi; Y W Ge; D K Lahiri; N H Greig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

Review 10.  All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease.

Authors:  Hyun-Pil Lee; Gemma Casadesus; Xiongwei Zhu; Hyoung-gon Lee; George Perry; Mark A Smith; Katarzyna Gustaw-Rothenberg; Alan Lerner
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.